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The androgen receptor (AR) antagonist enzalutamide is one of the
principal treatments for men with castration-resistant prostate
cancer (CRPC). However, not all patients respond, and resistance
mechanisms are largely unknown. We hypothesized that genomic
and transcriptional features from metastatic CRPC biopsies prior to
treatment would be predictive of de novo treatment resistance. To
this end, we conducted a phase II trial of enzalutamide treatment
(160 mg/d) in 36 men with metastatic CRPC. Thirty-four patients
were evaluable for the primary end point of a prostate-specific
antigen (PSA)50 response (PSA decline ≥50% at 12 wk vs. base-
line). Nine patients were classified as nonresponders (PSA
decline <50%), and 25 patients were classified as responders
(PSA decline ≥50%). Failure to achieve a PSA50 was associated
with shorter progression-free survival, time on treatment, and
overall survival, demonstrating PSA50’s utility. Targeted DNA-
sequencing was performed on 26 of 36 biopsies, and RNA-
sequencing was performed on 25 of 36 biopsies that contained
sufficient material. Using computational methods, we measured
AR transcriptional function and performed gene set enrichment
analysis (GSEA) to identify pathways whose activity state corre-
lated with de novo resistance. TP53 gene alterations were more
common in nonresponders, although this did not reach statistical
significance (P = 0.055). AR gene alterations and AR expression
were similar between groups. Importantly, however, transcrip-
tional measurements demonstrated that specific gene sets—
including those linked to low AR transcriptional activity and a
stemness program—were activated in nonresponders. Our results
suggest that patients whose tumors harbor this program should
be considered for clinical trials testing rational agents to overcome
de novo enzalutamide resistance.
enzalutamide | resistance | androgen receptor | stemness
We now know that persistent intratumoral androgens thatactivate the androgen receptor (AR) are commonly found
in castration-resistant prostate cancer (CRPC) tumors despite
androgen deprivation therapy (ADT). The main sites of andro-
gen production in men with CRPC include the adrenal glands
and tumor cells themselves. Because of this knowledge, new and
more potent inhibitors of androgen activation of the AR have
been developed in recent years (1–4). Importantly, treatment
with the androgen synthesis inhibitor abiraterone acetate or the
AR antagonist enzalutamide improves progression-free survival
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(PFS) and overall survival (OS) in patients with metastatic
CRPC (5–8). Furthermore, enzalutamide, apalutamide, and the
newer AR antagonist darolutamide all improve metastasis-free
survival in men with nonmetastatic CRPC (9–11).
Enzalutamide is commonly used in the first-line treatment of
men with CRPC. While the majority of patients with metastatic
CRPC benefit from enzalutamide treatment, nearly one-quarter
to one-half do not (5, 6). A few studies to date have prospectively
examined samples from men with enzalutamide-naïve CRPC to
identify determinants of response or resistance. However, these
studies have largely been restricted to mutational profiling, were
small in size, or focused on acquired—rather than de novo—
resistance (12–14). Thus, predictors and determinants of de novo
enzalutamide resistance in CRPC remain largely unknown.
We hypothesized that a more detailed characterization of the
genomic landscape of baseline CRPC samples in patients be-
ginning enzalutamide treatment would clarify determinants of de
novo resistance. To test this hypothesis, we initiated a multi-
institutional, prospective enzalutamide clinical trial in men with
metastatic CRPC who had a metastatic lesion amenable to a
pretreatment biopsy. In this report, we describe baseline geno-
mic and transcriptional features that differed between those
patients whose tumors either responded or failed to respond to
enzalutamide treatment.
Results
Patient Characteristics. The clinical trial Genetic and Molecular
Mechanisms in Assessing Response in Patients with Prostate
Cancer Receiving Enzalutamide Therapy enrolled 36 patients
with metastatic CRPC who had not previously received enzalu-
tamide. Patients with prior use of docetaxel or abiraterone were
ineligible for this study. Study enrollment, follow-up, and anal-
yses are depicted in SI Appendix, Fig. S1. The demographic
characteristics for all 36 patients enrolled on the study are shown
in SI Appendix, Table S1. Thirty-four patients were evaluable for
the primary end point of ≥50% PSA decline at 12 wk, and their
demographic features are shown in Table 1. There were 9 non-
responders (<50% PSA decline at 12 wk) and 25 responders
(≥50% PSA decline at 12 wk) (Fig. 1).
Clinical Outcomes. We next examined clinical outcomes for the
entirety of the trial participants and for the nonresponders vs.
responders. Thirty-eight percent (13 of 34) of evaluable patients
had radiographic responses by response evaluation criteria in
solid tumors (RECIST), and all radiographic responses were
seen in those with a PSA50 response. Overall median time on
treatment (TOT) was 14.4 mo. Overall median PFS was 11.03
mo, andOS was 25.11mo. Compared with responders, nonresponders
had a statistically significant shorter median TOT (3.4 vs. 24.2
mo, P < 0.001, hazard ratio (HR) = 4.90 [2.03 to 11.82]), PFS
(3.67 vs. 24 mo, P < 0.001, HR = 5.51 [2.2 to 13.81]), and OS
(15.97 vs. 36.6 mo, P < 0.001, HR = 4.41 [1.71 to 11.44]) (Fig. 2).
Thus, PSA50 response was a strong predictor of clinical benefit.
Targeted DNA-Sequencing. For 26 of 36 patients, there was suffi-
cient DNA to perform targeted DNA-sequencing (DNA-seq).
Five of these patients were nonresponders, and 21 were re-
sponders. We focused on TP53, RB1, and PTEN as those genes
have been linked previously to poor outcomes for men with
CRPC or resistance to AR-targeting therapies in preclinical or
clinical studies (12, 15–18). No statistically significant differences
were detected between the two groups for these genes (Fig. 3) or
other genes examined (SI Appendix, Fig. S2). However, there was
a strong trend toward greater likelihood of TP53 alterations in
nonresponders (Fisher’s exact test P = 0.055).
Assessments of AR Genomic Aberrations and Expression. Since AR is
the target of enzalutamide, we next determined if there were
genomic differences in the AR between groups using AR DNA-
seq. Of the 22 unique patients who had AR DNA-seq data, there
were 3 nonresponders and 19 responders. No statistically sig-
nificant differences in AR genomic alterations were found be-
tween these two groups (Fig. 4A). We next quantified ARmRNA
expression in the 25 patients whose tumors underwent RNA-
sequencing (RNA-seq): 7 nonresponders and 18 responders.
AR messenger ribonuleic acid (mRNA) expression was similar
between both groups (Fig. 4B). Furthermore, expression levels of
the transcript variant AR-V7 were low and were similar between
both groups (Fig. 4C). AR immunohistochemistry was available
in 22 patients. Strong, nuclear AR staining was present in tumors
from all 6 nonresponder samples and in all 15 responder samples
that were tested (SI Appendix, Table S2). Representative exam-
ples are shown in Fig. 4D. Thus, neither alterations in the AR
gene nor AR expression correlated with de novo enzalutamide
resistance.
Pathway Analysis. Next, we sought to determine if there were
differentially activated pathways in nonresponders vs. responders
in the RNA-seq data. To identify these pathways, we performed
gene set enrichment analysis (GSEA) using all candidate gene
sets within the Hallmark database. This analysis determined that
baseline tumors from nonresponders vs. responders had enrich-
ment of 18 statistically significant pathways using a false dis-
covery rate (FDR) q-value cutoff of 0.05 (Fig. 5A and SI
Appendix, Fig. S3). Epithelial mesenchymal transition (EMT)
was the top gene set activated in nonresponders, and other
pathways linked to EMT, including IL-6/Jak/Stat3 signaling,
TGF-β signaling, and TNFα signaling via NFΚB, were also ac-
tivated. Furthermore, immune hallmark pathways were also ac-
tivated in nonresponders, including IFN-α, IFN-γ, allograft
rejection, inflammatory response, and complement.
AR Activity Measurements. AR signaling was not one of the top
gene sets differentially activated between nonresponders and
responders. However, there were many gene sets activated in
enzalutamide nonresponders in our trial—including those linked
to EMT, stemness, and immune hallmarks—that were also ac-
tivated in subsets of localized, hormone-naïve prostate cancer
that had low AR activity in a recent report from our group (19).
Importantly, low AR activity in that prior report was associated
with shorter metastasis-free survival or time to biochemical re-
currence, demonstrating the clinical significance of AR activity-
low prostate cancers and the utility of this signature (the Spratt
signature) (19). Therefore, we next measured AR function in
RNA-seq data from our enzalutamide trial specimens using the
Spratt signature. There was a strong trend toward reduced AR
Significance
The androgen receptor (AR) antagonist enzalutamide is one of
the principal treatments for men with metastatic castration-
resistant prostate cancer. However, not all patients respond,
and de novo resistance mechanisms are largely unknown. To
clarify mechanisms that contribute to enzalutamide resistance,
we conducted a single-arm enzalutamide clinical trial. Meta-
static tissue biopsies were required prior to study entry so we
could attempt to identify molecular features associated with
de novo resistance. Transcriptional profiling identified specific
gene sets—including those linked to reduced AR transcriptional
activity and a stemness program—that were activated in
nonresponders. Our results suggest that patients whose tu-
mors harbor this program should be considered for clinical
trials testing rational agents to overcome de novo
enzalutamide resistance.
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activity in nonresponders vs. responders using this signature
(Wilcoxon rank sum test P = 0.06) (SI Appendix, Fig. S4). We
also quantified AR activity using the Virtual Inference of Protein
activity by Enriched Regulon analysis (VIPER) algorithm (20).
VIPER analysis also demonstrated that enzalutamide nonre-
sponders had lower AR activity (Fig. 5B). Overall, these results
suggest that low AR transcriptional activity—rather than AR
genomic changes or altered AR expression—may contribute to
de novo enzalutamide resistance.
Stemness and Lineage Signature Measurements. Low AR activity
has been linked to stemness and lineage plasticity, or change in
differentiation state, that are now recognized as a common cause
of acquired resistance to AR-targeting therapies (21–25). Im-
portantly, all of the baseline tumors from our study were ade-
nocarcinomas, and most prostate adenocarcinoma tumors
express a luminal lineage program (22). However, a basal line-
age, neurogenic/stemness program is present in a subset of pa-
tients and is linked with prostate cancer aggressiveness (26, 27).
Indeed, prior work demonstrated that localized prostate tumors
with a basal lineage program are much less likely to respond to
ADT vs. patients whose tumors harbor a luminal lineage pro-
gram (22). Therefore, we next sought to measure signatures of
these lineages (26) and determine if they were differentially ac-
tivated between nonresponders and responders. Our analysis
demonstrates that a basal lineage, neurogenic/stemness program
is activated in nonresponders to enzalutamide treatment, while a
luminal lineage program is more activated in responders
(Fig. 5C), corroborating the prior work in prostate cancer ex-
amining the effect of basal lineage on promoting resistance to
ADT (22).
To more fully examine the role of neurogenic gene expression,
we determined if a set of genes used previously to distinguish
neuroendocrine prostate cancer (NEPC) vs. adenocarcinoma
patient tumors (28) was differentially expressed in nonre-
sponders vs. responders. Importantly, genes up-regulated in
NEPC patient tumors from that prior report were activated in
nonresponders vs. responders; genes down-regulated in NEPC
patient tumors from that prior report—many linked to AR
activity—were deactivated in nonresponders from our trial
(Fig. 5D). These results further suggest that nonresponder tu-
mors have features of stemness and corroborate our findings
suggesting that AR activity is lower in nonresponders. In sum-
mary, results from this clinical trial suggest that an AR activity-
low, stemness program may contribute to de novo enzalutamide
resistance.
Discussion
Two large, randomized, phase III trials demonstrate that enza-
lutamide treatment improves PFS and OS for men with meta-
static CRPC (5, 6). Enzalutamide also improves PFS for men
with nonmetastatic CRPC and OS and/or PFS for men with
hormone-naïve metastatic prostate cancer in two additional
clinical trials (10, 29, 30). However, approximately one-third of
patients do not respond to enzalutamide treatment, and very
little is known about determinants of de novo enzalutamide re-
sistance in metastatic CRPC (5, 6). The Genetic and Molecular
Mechanisms in Assessing Response in Patients with Prostate Cancer
Table 1. Baseline patient characteristics
Characteristic
All evaluable
patients (n = 34)
Age (y)
Median 72.3
Range 56.6–88.7
Total Gleason score, n (%)
6 2 (5.9)
7 13 (38.2)
8 3 (8.8)
9 10 (29.4)
Unavailable 6 (17.6)
Metastatic sites at time of biopsy, n (%)
Bone 25 (73.5)
Lung 2 (5.9)
Liver 0 (0.0)
Visceral (other than lung and liver)* 1 (2.9)
Lymph nodes 6 (17.6)
ECOG performance status score, n (%)
0 20 (58.8)
1 14 (41.2)
2–4 0 (0.0)
PSA
Median 36.6
Range 2.3–2,137.3
Patient demographics for evaluable patients. Demographic information
for the 34 evaluable patients is shown. ECOG, Eastern Cooperative
Oncology Group.
*Ischioanal fossa mass.
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Fig. 1. PSA waterfall plot. PSA change from baseline for patients by response group (9 nonresponders and 25 responders). Each bar represents one patient
with patient identification indicated along zero axis. PSA response was determined based on change at 12 wk vs. the baseline value.
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Fig. 2. Kaplan–Meier curves stratified by PSA response. Tick marks indicate censoring events. P values were determined using the log-rank test to compare
outcome measures between nonresponders and responders. (A) TOT. Probability that patients remain on treatment during follow-up in months. (B) PFS.
Probability that patients are alive and without evidence of disease progression during follow-up in months. One subject was excluded due to missing pro-
gression information. (C) OS. Probability that patients are still alive during follow-up in months.
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Receiving Enzalutamide Therapy clinical trial was designed to
address this deficit. To identify molecular predictors of enzalu-
tamide response, we performed both targeted DNA-seq and
RNA-seq of tumors from prospectively collected pretreatment
metastatic biopsies. Correlating the molecular features from
these assays with the primary end point of ≥50% PSA decline 12
wk after starting enzalutamide treatment—that we confirmed to
be a strong predictor of patient outcome (Fig. 2)—enabled us to
identify factors associated with de novo resistance.
It is noteworthy that the patients enrolled on our trial had a
lower PSA response rate, TOT, PFS, and OS than patients
with metastatic CRPC enrolled on the PREVAIL trial who
had not previously received enzalutamide, abiraterone, or
docetaxel (5). There are several key differences between our
trial and PREVAIL that may help explain these results. First,
our trial—unlike PREVAIL—allowed enrollment of patients
with symptomatic metastases. Second, our trial mandated that
all eligible patients have a metastatic lesion that was amenable
to biopsy. Thus, it is quite likely that the patients enrolled on
our trial had more aggressive or advanced disease than those
enrolled on PREVAIL, thus explaining the differences in
outcomes.
Our institutional targeted DNA-seq panel did not detect any
statistically significant differences in mutations found between
nonresponders and responders. However, we did observe a
strong trend toward statistical significance for TP53 mutations
that were more common in nonresponders (4 of 5 vs. 6 of 21,
Fisher’s exact test P = 0.055) (Fig. 3). This is consistent with
previous findings by Annala et al. (12) who used cell-free DNA-
seq of enzalutamide- or abiraterone-naïve patients and determined
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Fig. 3. DNA-seq results for TP53, PTEN, and RB1. An OncoPrint reflecting the copy number alteration and mutation status for the indicated genes in re-
sponders and nonresponders is shown.
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D
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Fig. 4. AR DNA-seq results and expression status. (A) An OncoPrint reflecting the copy number alteration and mutation status of the AR in responders and
nonresponders is shown. (B and C) Boxplots of the mRNA expression of the AR (B) and AR-V7 (C) in nonresponders and responders are shown. Wilcoxon rank
sum test was used to test the difference between the two groups. (D) Representative AR immunohistochemistry staining is shown for two patients.
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that alterations in TP53 were associated with poor outcomes.
Furthermore, loss of TP53 has been linked to increased cellular
reprogramming efficiency (31) or stemness/lineage plasticity (16,
17)—programs that we find to be enriched in nonresponders
(Fig. 5 C and D). This suggest that TP53 alterations may contribute
to the gene expression changes we observed in nonresponders vs.
responders.
Because AR is the target of enzalutamide, we also examined
alterations in the AR gene itself as well as measurements of AR
transcriptional function. We did not observe statistically signifi-
cant differences in AR gene alterations between the two groups
(Fig. 4A), although this may be due to sample size limitations
and the fact that not every patient had AR DNA-seq data
available. Importantly, we did measure AR mRNA and protein
A
C
D
B
Fig. 5. Transcriptional measurements implicate an AR activity-low, stemness program in nonresponders. (A) Results from the GSEA pathway analysis using
the Broad Hallmark pathways are shown. The 18 hallmark pathways activated in the nonresponders with FDR q value < 0.05 are shown. *FDR q value < 0.05;
**FDR q value < 1e-3; ***FDR q value < 1e-6. (B) Boxplot indicates the AR activity differences between nonresponders and responders. Significance of the
difference between nonresponders and responders was calculated using the Wilcoxon rank sum test. (C) Basal and luminal signature enrichment plots for
nonresponders and responders with FDR q values are shown. (D) Beltran NEPC up-regulated and down-regulated gene set enrichment plots for non-
responders and responders with FDR q values are shown.
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expression. Levels of AR mRNA and protein expression were
also similar between nonresponders and responders (Fig. 4B and
SI Appendix, Table S2), suggesting that AR genomic changes or
AR expression changes are not good predictors of enzalutamide
response. Furthermore, expression levels of AR-V7 were low in
both nonresponders and responders (Fig. 4C), which may be
attributable to the fact that none of the patients had been treated
previously with novel, potent AR inhibitors like enzalutamide or
abiraterone. Conversely, we determined that lower AR tran-
scriptional activity was associated with enzalutamide resistance
using two independent measurements of AR function (Fig. 5B
and SI Appendix, Fig. S4). Because AR is the target of enzalu-
tamide, intuitively, this makes sense and strongly suggests that
tumors with lower AR function are less AR signaling dependent
and thus, less likely to respond to enzalutamide treatment. Un-
derstanding factors that lead to reduced AR activity despite
persistent AR expression—inactivation of essential cofactors or
chromatin conformation not conducive to AR activity—will be
important to develop strategies to resensitize these tumors to
drugs like enzalutamide.
Low AR activity has been linked to lineage plasticity, EMT, or
stemness (19, 23–26). Importantly, GSEA of differentially
expressed genes identified 18 pathways (P < 0.05) that were
activated in tumors from patients with de novo enzalutamide
resistance—most notably pathways that are often linked to
stemness, lineage plasticity, or EMT (32). None of the histologic
sections from our biopsies demonstrated a mesenchymal mor-
phology or phenotype, so we believe that the GSEA results may
indicate a partial EMT, stem-like state that has been previously
linked to self-renewal and treatment resistance (33, 34). This
interpretation is in keeping with the enrichment of a stemness
signature (26) in nonresponder patients (Fig. 5 C and D). In-
deed, a previously described basal lineage, neurogenic, stemness
signature (26) was activated in nonresponders from our trial
(Fig. 5C). Furthermore, we found that a gene set used previously
to distinguish NEPC vs. adenocarcinoma patient tumors linked
to lower AR activity (26) was differentially expressed in nonre-
sponders vs. responders (Fig. 5D). The sum of these results
suggests that reduced AR activity may promote a stemness
program or that activation of this stemness program leads to
reduced AR activity. While it is uncertain which event occurs
first, it is clear that the presence of low AR activity and a
stemness program are linked to de novo enzalutamide resistance.
Considerable prior work has shown that stemness-associated
pathways are associated with acquired resistance to AR pathway
inhibition (32). Indeed, previous work demonstrates that the IL-
6–JAK-STAT3 signaling pathway is activated in tumors resistant
to AR pathway inhibition and that IL-6–JAK-STAT3 promotes
stem-like properties, EMT, and lineage plasticity (35). GSEA
also implicated activation of the TGF-β signaling pathway that is
upstream of SMAD3 in nonresponders. SMAD3 up-regulation
was previously shown by Pal et al. (14) to mediate TGF-β as well
as cyclin D1 signaling in circulating tumor cell samples from
patients with acquired resistance to enzalutamide. However, our
work demonstrates enrichment of IL-6–JAK-STAT3 and TGF-β
pathways in CRPC patient tumors even prior to enzalutamide
treatment and suggests that activation of these pathways may
contribute to de novo enzalutamide resistance. Finally, that there
are drugs to block key members of these pathways [e.g., IL-6
inhibitor siltuximab (36), JAK inhibitor ruxolitinib (37), STAT3
degraders (38), TGF-β receptor inhibitor galunisertib (39), and
CDK4/6 inhibitors (40)] that target cyclin D1 suggests that it may
be possible in the near term to determine if these drugs may
overcome de novo enzalutamide resistance. One way to enrich
these trials with appropriate subjects most likely to have de novo
enzalutamide resistance is by using RNA-seq like in our trial.
Importantly, Clinical Laboratory Improvement Amendments
(CLIA) RNA-seq is now available commercially and at centers
such as ours (University of Michigan), and results are often
available within a 4-wk timeframe.
Low AR activity has also been linked to immune pathways
(19). Indeed, IFN-γ, IFN-α, allograft rejection, and inflammatory
response were also among the top gene sets activated in non-
responders (Fig. 5A). This suggests that differences in immune
activation may contribute to enzalutamide response. Our sam-
ples underwent laser-capture microdissection to enrich for tumor
cells prior to RNA-seq. Thus, it is not possible to reliably mea-
sure transcriptional signatures linked to nonepithelial cell types
and deconvolute the tumor microenvironment. However, despite
the approval of the autologous DNA vaccine sipuleucel-T (41) in
2011, phase III trials of anti-CTLA4 checkpoint inhibition have
been disappointing in CRPC (42, 43), and anti-PD1 trials in men
with metastatic CRPC have not demonstrated high response
rates or durability of tumor control (44). In the future, it will be
important to determine if immunotherapeutic agents may be
useful for overcoming de novo enzalutamide resistance and to
determine if differences in the microenvironmental components
of tumors contribute to resistance to immunotherapy and drugs
such as enzalutamide.
Despite the importance of our findings, there are several
limitations of our study. First, fewer patients than anticipated
had sufficient material for all of the molecular analyses. This is
not unique to this study and is attributable to the fact that many
of our patients underwent biopsies of metastatic bone lesions
from which it can be challenging to obtain high-quality material
for sequencing. Nonetheless, our study is the largest prospective
clinical trial examining molecular predictors of enzalutamide
response from metastatic tumor biopsies, and we look forward to
the results of other studies with novel AR-targeting agents that
may help to validate our results. Second, another limitation of
our study is that mutational profiling primarily consisted of tar-
geted DNA-seq rather than whole–exome-sequencing or whole–
genome-sequencing (whole–genome-seq), limiting the number of
genes examined across all patients. However, our panel did in-
clude key genes previously linked to enzalutamide resistance or
EMT/lineage plasticity [TP53, RB1, and PTEN (12, 15–18)], and
significant differences were not found. We cannot rule out that
loss of function of these genes or others through epigenetic or
posttranscriptional mechanisms could have also contributed to de
novo enzalutamide resistance.
A further limitation of our study is that only a single metastatic
site was biopsied prior to treatment, although it remains chal-
lenging to collect biopsies from multiple sites at the same time
point. However, despite only obtaining a biopsy from a single
site, we did determine that the site sampled had molecular fea-
tures that strongly correlated with de novo enzalutamide re-
sistance. This suggests that a single-site biopsy—if it contains
adequate material for sequencing—may be sufficient to identify
markers of enzalutamide response using the approach we de-
scribe herein. Indeed, our comprehensive transcriptome-based
analysis with GSEA identified pathways and lineage signatures
not previously linked to de novo clinical enzalutamide resistance.
In summary, this is the largest prospective enzalutamide clin-
ical trial to perform mutational and transcriptional profiling of
enzalutamide-naïve, metastatic CRPC biopsy samples. Impor-
tantly, using transcriptional profiling and GSEA, we identified
several targetable pathways that may contribute to an AR
activity-low, stemness program linked to de novo enzalutamide
resistance. In the future, it will be important to determine
whether mechanisms identified herein are also relevant to men
who present with ADT- and enzalutamide-naïve prostate cancer
because of the recent approval of enzalutamide in that setting,
along with abiraterone and apalutamide. Moreover, it will be
important to determine which specific factors that regulate the
phenotype described herein are most critical for de novo enza-
lutamide resistance. Such experiments may provide the rationale
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to target these factors alone or in combination with enzaluta-
mide in patients like those identified herein who are least likely
to respond to enzalutamide monotherapy.
Materials and Methods
Study Design and Patients. The clinical trial Genetic and Molecular Mecha-
nisms in Assessing Response in Patients with Prostate Cancer Receiving
Enzalutamide Therapy (principal investigator: J.J.A.) was registered on
clinicaltrials.gov (NCT02099864). This was a multicenter, single-arm, phase
II study evaluating baseline predictors of response to enzalutamide therapy
in men with metastatic CRPC who had not received prior enzalutamide,
abiraterone, or docetaxel. Institutional review board (IRB) approval was
obtained at the participating centers (Oregon Health & Science University
and the University of California, San Francisco) prior to enrollment of the
first patient at each center. Written informed consent was obtained from all
patients prior to participation in the study.
All eligible patients had a metastatic lesion amenable to image-guided
biopsy. Prior to initiation of enzalutamide treatment, subjects underwent an
image-guided biopsy of a metastatic lesion to obtain tumor tissue for
baseline genomic analyses. Subjects received enzalutamide for the duration
of the study and were assessed for clinical or radiographic progression every
12 wk. Study treatment was continued until withdrawal of consent, un-
acceptable toxicity, disease progression, or death.
Traditional power calculations cannot be used to determine the number of
samples (i.e., patients) required because the assumptions of independence
and normality do not hold (45). An alternative approach is to model this
problem as a learning curve in which the classification error is characterized
as an inverse power law (46): error = an−α + b, where error is the expected
error rate given n training samples, a is the learning rate, α is the decay rate,
and b is the Bayes error, or minimum error achievable. This approach has
been applied to several cancer classification problems, and estimates for the
variables can be found in the literature (46). For our purposes, we used the
average values from seven cancer datasets to estimate a, α, and b. With a =
0.736, α = 0.65, and b = 0.001, we can estimate the error for various sample
sizes. Prior literature demonstrates an ∼70% PSA response rate with enza-
lutamide in a similar patient population (5). Therefore, we estimated that
we would need to enroll 36 patients, allowing for a 20% biopsy failure rate,
to yield 30 patients with evaluable tumors (20 responders and 10 nonre-
sponders) and that 30 patients would achieve an error rate of ∼0.08.
Per the Prostate Cancer Clinical Trials Working Group-2 criteria, disease
progression was defined as radiographic progression (based on RECIST 1.1
criteria for soft tissue disease measured by computerized tomography (CT)
scan or the appearance of two or more unequivocal bone lesions on bone
scan) or clinical progression; PSA progression alone did not meet criteria for
discontinuation of study treatment (47). Patients who discontinued treat-
ment despite not meeting study-defined progression continued to be fol-
lowed until they met progression criteria. Following discontinuation of study
treatment, all subjects were followed for OS.
For the primary analysis, we assessed correlations between baseline mo-
lecular features and PSA50 response defined as a PSA decline of ≥50% at 12
wk compared with baseline. Secondary clinical end points included TOT, PFS,
and OS, all measured from the date of enzalutamide initiation.
Thirty-six men with enzalutamide-, abiraterone-, and docetaxel-naïve
metastatic CRPC progressing on ADT and who were eligible to receive
treatment with enzalutamide were enrolled (SI Appendix, Fig. S1). Two
subjects were not evaluable for analysis of the primary end point (≥50% PSA
decline at 12 wk). One subject was excluded because of incomplete PSA
data. The second patient was excluded because his PSA fell on treatment in
the setting of rapid progression of disease, concerning for conversion to
neuroendocrine prostate cancer; thus, it was determined that this subject’s
PSA decline was not consistent with response. Therefore, a total of 34 pa-
tients were evaluable for analysis of the primary end point. Their clinical trial
identification numbers are shown. SI Appendix, Fig. S1 includes information
on the number of patients who underwent each molecular assay.
Statistical Analysis. Descriptive statistics (median and interquartile range for
continuous variables; frequencies and percentages for categorical variables)
were used to summarize the demographic and clinical data by response
group. Time-to-event analysis was performed using Kaplan–Meier curves
and log-rank tests to evaluate the association between response group and
TOT, PFS, and OS. Cox regression models were used to calculate hazard ra-
tios by response group with 95% CIs. All statistical analyses were performed
using R: A Language and Environment for Statistical Computing. P < 0.05
was considered statistically significant.
Analysis of Baseline Biopsy Samples and DNA-Seq. At the time of consenting
for the Genetic and Molecular Mechanisms in Assessing Response in Patients
with Prostate Cancer Receiving Enzalutamide Therapy trial, patients also
consented to the IRB-approved West Coast Prostate Cancer Dream Team
tissue collection protocol through which their tumor samples were se-
quenced. Results in Fig. 3 and SI Appendix, Fig. S2 are based on a 37-gene
targeted DNA-seq panel described previously (48). AR DNA-seq results in
Fig. 4A are based on an alternate targeted DNA-seq panel that included the
AR or whole–genome-seq that has been described previously (21, 49).
Characterization of AR Protein Expression. AR protein expression was analyzed
using immunohistochemical analysis. The AR [C6F11] XP rabbit monoclonal
antibody was used as previously described, and AR nuclear staining was
quantified as described previously: 0 (absent), 1+ (low), 2+ (intermediate),
and 3+ (strong) (21).
Transcriptional Profiling. Tumor cores were frozen in optimized cutting
temperature (OCT) medium and underwent laser capture microdissection
using methods described previously (49). The raw read counts and transcripts
per kilobase million (TPM) of the gene expression measurements were de-
rived by RSEM (50) based on the GRCh37 GENCODE version 19 (Ensembl 74)
gene annotation. To filter out low-expressed genes, we required that the
genes have TPM greater than one in at least three samples for further
analysis. The TPM gene expression data quantified by RSEM from the RNA-
seq may be found in Dataset S1; sample identifications highlighted in blue
indicate responders, while those highlighted in red indicate nonresponders.
GSEA Pathway Analysis. GSEA version 3.0 (51) was used to identify gene sets that
were significantly activated in enzalutamide nonresponders compared with re-
sponders from the Hallmark database (52). The expression data normalized by
variance stabilizing transformation in DESeq2 (53) were used as the input of
GSEA, and the default metric Signal2Noise in GSEA was applied to calculate the
differential expression with respect to the responders and nonresponders. The
gene sets were considered to be activated if their FDR q value was less than 0.05.
AR Activity Analysis. The Spratt AR activity scoreswere calculated based on nine
genes described previously (19). Tomeasure AR activity, we also used the VIPER
R package (20). The input for VIPER is the log2 transformed TPM gene ex-
pression matrix of all samples. The regulon used for the AR activity used in
VIPER analysis was curated from four databases as previously described (54).
Basal and Luminal Lineage Signature Analysis. The Zhang Basal and Luminal
gene signatures have been described previously (26). First, GSEA was used to
determine whether the two signatures showed significant, concordant differ-
ences between the nonresponder and responder groups. Second, to quantify the
activities of the two signatures in each sample, we used the single-sample gene
set enrichment analysis (ssGSEA) (55) implemented in the GSVA (56) R package.
ssGSEA is a rank-based comparison to access the expression levels of genes in the
gene set against all other genes based on the expression profile of one sample.
FDR q values were used to determine statistical significance.
NEPC Signature Analysis.We used the previously described Beltran NEPC gene
signature (28) to build gene sets. Specifically, 29 genes up-regulated in NEPC
vs. adenocarcinoma patient tumors or 41 genes down-regulated in NEPC vs.
adenocarcinoma patient tumors were used to develop two gene sets. We
then used GSEA to determine whether each gene set showed enrichment
differences between nonresponders and responders.
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